[go: up one dir, main page]

AR119303A1 - Anticuerpo anti-epha4 humano - Google Patents

Anticuerpo anti-epha4 humano

Info

Publication number
AR119303A1
AR119303A1 ARP200101834A ARP200101834A AR119303A1 AR 119303 A1 AR119303 A1 AR 119303A1 AR P200101834 A ARP200101834 A AR P200101834A AR P200101834 A ARP200101834 A AR P200101834A AR 119303 A1 AR119303 A1 AR 119303A1
Authority
AR
Argentina
Prior art keywords
epha4
antibody
epha4 antibody
human anti
mouse anti
Prior art date
Application number
ARP200101834A
Other languages
English (en)
Inventor
Eiji Inoue
Akio Yamada
Tomomi Kawakatsu
Toshio Imai
Maki Deguchi
Aki Nakatani
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of AR119303A1 publication Critical patent/AR119303A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporciona un anticuerpo anti-EphA4 que puede unirse a EphA4 y potenciar la escisión de EphA4, así como una composición farmacéutica que comprende el anticuerpo como el principio activo. Se obtuvo un anticuerpo anti-EphA4 de ratón que tiene afinidad de unión hacia EphA4 y puede potenciar la escisión de EphA4, y se identificó la secuencia de la región determinante de complementariedad (CDR) del anticuerpo anti-EphA4 de ratón. Posteriormente, se obtuvo el anticuerpo anti-EphA4 de interés produciendo un anticuerpo humanizado del anticuerpo anti-EphA4 de ratón.
ARP200101834A 2019-07-01 2020-06-29 Anticuerpo anti-epha4 humano AR119303A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019122982 2019-07-01

Publications (1)

Publication Number Publication Date
AR119303A1 true AR119303A1 (es) 2021-12-09

Family

ID=74066003

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101834A AR119303A1 (es) 2019-07-01 2020-06-29 Anticuerpo anti-epha4 humano

Country Status (24)

Country Link
US (2) US10947313B2 (es)
EP (1) EP3995582A4 (es)
JP (2) JP6979147B2 (es)
KR (1) KR20220027825A (es)
CN (2) CN113906050B (es)
AR (1) AR119303A1 (es)
AU (1) AU2020300205A1 (es)
BR (1) BR112021025161A2 (es)
CA (1) CA3139398A1 (es)
CL (1) CL2021003326A1 (es)
CO (1) CO2021016588A2 (es)
IL (1) IL287828A (es)
JO (1) JOP20210333A1 (es)
MA (1) MA56466A (es)
MX (1) MX2021015298A (es)
MY (1) MY207780A (es)
NZ (1) NZ783106A (es)
PE (1) PE20220570A1 (es)
PH (1) PH12021553090A1 (es)
SG (1) SG11202112433VA (es)
TW (3) TWI779307B (es)
UA (1) UA129772C2 (es)
WO (1) WO2021002312A1 (es)
ZA (1) ZA202108836B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
MX2023004848A (es) * 2020-12-24 2023-05-10 Eisai R&D Man Co Ltd Composicion farmaceutica terapeutica para tratar la esclerosis lateral amiotrofica.
US20240385190A1 (en) * 2021-11-11 2024-11-21 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
WO2025151607A1 (en) * 2024-01-10 2025-07-17 Santa Ana Bio, Inc. Methods and compositions for treating autoimmune, allergic and inflammatory diseases

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1094731A (en) 1911-06-06 1914-04-28 Lucien Linden Oxidizing process.
JP2824433B2 (ja) 1988-12-09 1998-11-11 財団法人化学及血清療法研究所 新規なハイブリッドプロモーターおよびこれを組み込んだ外来遺伝子発現用ベクター
AU629554B2 (en) 1988-06-24 1992-10-08 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Exogenous gene expression vector containing chick beta-actin gene promoter
JP3680114B2 (ja) 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
US5902732A (en) 1995-10-04 1999-05-11 Cytoscan Sciences Llc Drug screening process measuring changes in cell volume
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US20020068361A1 (en) 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
US5876946A (en) 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
US20070026409A1 (en) 2001-08-14 2007-02-01 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US20060241074A1 (en) 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
EP1478772A2 (en) 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
JP2003169699A (ja) 2001-12-10 2003-06-17 Japan Science & Technology Corp 特異的γプロテアーゼ阻害剤のスクリーニング方法
JP2004000060A (ja) 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
CA2499580A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
HRP20050461A2 (en) 2002-11-26 2005-08-31 Pharmacia & Upjohn Company Llc Soluble notch-based substrates for gamma secretase and methods and compositions for using same
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
JPWO2005045028A1 (ja) 2003-11-10 2007-05-17 財団法人大阪産業振興機構 セル・フリー・Ｎｏｔｃｈ切断分析方法及び薬剤スクリーニング方法
JP2007525203A (ja) 2004-02-27 2007-09-06 オンコセラピー・サイエンス株式会社 ＰＲＣおよびＰＤＡＣａの治療標的としてのＥｐｈＡ４
WO2006026820A1 (en) 2004-09-08 2006-03-16 The University Of Queensland Treating gliosis, glial scarring, inflammation or inhibition of axonal growth in the nervous system by modulating eph receptor
EP1662259A1 (en) 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
GB0427023D0 (en) 2004-12-09 2005-01-12 Merck Sharp & Dohme Assay method
CN101432022A (zh) 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗-EphA4抗体效应物作用损伤细胞的方法
EP1947193A1 (en) 2007-01-17 2008-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening method for anti-diabetic compounds
EP2166110B1 (en) 2007-06-08 2012-02-22 Eisai R&D Management Co., Ltd. Screening method utilizing novel substrate epha4 for gamma-secretase
US20090023158A1 (en) 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase
EP2177623A4 (en) 2007-07-19 2010-12-29 Eisai R&D Man Co Ltd SCREENING METHOD USING C-MET, A NEW SUBSTRATE FOR GAMMA SECRETASE
JPWO2009017234A1 (ja) 2007-08-01 2010-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質ｃ−Ｒｅｔを利用したスクリーニング方法
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
US20090163594A1 (en) 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
US8530181B2 (en) 2007-11-15 2013-09-10 Eisai R&D Management Co., Ltd. Method of screening for compounds which affect the cleavage of EphA7 byγ-secretase
DK2223999T3 (en) 2007-11-30 2017-12-18 Eisai R&D Man Co Ltd EPHA4 POLYPEPTIDE WITH UNKNOWN ACTIVITY AND USE THEREOF
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2260864A1 (en) 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications
JP2010285413A (ja) 2009-06-10 2010-12-24 Univ Of Melbourne 治療用途
US8865426B2 (en) * 2010-12-17 2014-10-21 Eisai R&D Management Co., Ltd. Screening method using gelatinase-mediated EphA4 cleavage reaction as an indicator
JP5961608B2 (ja) 2011-04-25 2016-08-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
GB201107996D0 (en) 2011-05-13 2011-06-29 Vib Vzw EphA4 is a diease modifier in motor neuron disease
ES2925224T3 (es) 2014-07-31 2022-10-14 Us Gov Health & Human Services Anticuerpos monoclonales humanos contra EphA4 y su uso
JP6738814B2 (ja) * 2015-09-08 2020-08-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ＥｐｈＡ４抗体
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano

Also Published As

Publication number Publication date
PH12021553090A1 (en) 2022-07-25
WO2021002312A1 (ja) 2021-01-07
JPWO2021002312A1 (ja) 2021-09-13
US11136400B2 (en) 2021-10-05
MY207780A (en) 2025-03-18
CN113906050A (zh) 2022-01-07
JP6979147B2 (ja) 2021-12-08
PE20220570A1 (es) 2022-04-20
ZA202108836B (en) 2023-04-26
AU2020300205A1 (en) 2022-01-20
TWI866304B (zh) 2024-12-11
MX2021015298A (es) 2022-01-18
CN113906050B (zh) 2023-11-21
CA3139398A1 (en) 2021-01-07
TWI808882B (zh) 2023-07-11
MA56466A (fr) 2022-05-11
EP3995582A4 (en) 2023-01-18
UA129772C2 (uk) 2025-07-30
NZ783106A (en) 2025-08-29
CN117398459A (zh) 2024-01-16
SG11202112433VA (en) 2021-12-30
EP3995582A1 (en) 2022-05-11
KR20220027825A (ko) 2022-03-08
JOP20210333A1 (ar) 2023-01-30
TW202115116A (zh) 2021-04-16
US20210171644A1 (en) 2021-06-10
US10947313B2 (en) 2021-03-16
JP7072114B2 (ja) 2022-05-19
TW202248216A (zh) 2022-12-16
IL287828A (en) 2022-01-01
CO2021016588A2 (es) 2022-04-08
TW202342101A (zh) 2023-11-01
CL2021003326A1 (es) 2022-07-22
TWI779307B (zh) 2022-10-01
BR112021025161A2 (pt) 2022-01-25
JP2022031271A (ja) 2022-02-18
US20210002378A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
CL2021003326A1 (es) Anticuerpo anti-epha4 humano.
AR104250A1 (es) Anticuerpo anti-notch4 humano
PH12020500177A1 (en) Bcma monoclonal antibody-drug conjugate
MX2021007320A (es) Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor.
MX2020008181A (es) Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo.
EA201391713A1 (ru) Нейтрализующие вирус иммунодефицита человека антитела и способы их применения
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
PE20150002A1 (es) Anticuerpos anti-fcrn
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
AR096687A1 (es) Anticuerpos anti-fcrh5
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
NI201900043A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
MX2015017487A (es) Anticuerpos cd3 humanizados o quimericos.
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
EA201691225A1 (ru) Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
WO2018187706A3 (en) Anti-influenza b virus neuraminidase antibodies and uses thereof
CO2018000652A2 (es) Anticuerpo anti-epha4
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.